Chinook Therapeutics Inc logo

KDNY

Chinook Therapeutics Inc

$21.67

Earnings Summary

Revenue
$2.7Mn
Net Profits
$-31.68Mn
Net Profit Margins
-1174.79%

Highlights

Revenue:

Chinook Therapeutics Inc’s revenue jumped 668.38% since last year same period to $2.7Mn in the Q1 2022. On a quarterly growth basis, Chinook Therapeutics Inc has generated 818.48% jump in its revenue since last 3-months.

Net Profits:

Chinook Therapeutics Inc’s net profit jumped 14.86% since last year same period to $-31.68Mn in the Q1 2022. On a quarterly growth basis, Chinook Therapeutics Inc has generated -128.7% fall in its net profits since last 3-months.

Net Profit Margins:

Chinook Therapeutics Inc’s net profit margin jumped 88.92% since last year same period to -1174.79% in the Q1 2022. On a quarterly growth basis, Chinook Therapeutics Inc has generated 96% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Chinook Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.61
EPS Estimate Current Year
-0.61

Highlights

EPS Estimate Current Quarter:

Chinook Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 8.96% jump from last quarter’s estimates.

EPS Estimate Current Year:

Chinook Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.61.

Key Ratios

Key ratios of the Chinook Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.54
Return on Assets (ROA)
-0.1
Return on Equity (ROE)
-0.23
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Chinook Therapeutics Inc’s earning per share (EPS) jumped 56.45% since last year same period to -0.54 in the Q1 2022. This indicates that the Chinook Therapeutics Inc has generated 56.45% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Chinook Therapeutics Inc’s return on assets (ROA) stands at -0.1.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Chinook Therapeutics Inc’s return on equity (ROE) stands at -0.23.

Dividend Per Share (DPS):

Chinook Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.67
-0.54
19.4%

Company Information

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

Organisation
Chinook Therapeutics Inc
Headquarters
Berkeley, California, US
Employees
105
Industry
Health Technology
CEO
Stephen Isaacs